SevenScore Pharmaceuticals LLC made a proposal to acquire Regnum Corp. (OTCPK:RGMP) from Phoenixus AG and others in a reverse merger transaction for $9.8 million on April 7, 2021. SevenScore Pharmaceuticals LLC entered into an agreement to acquire Regnum Corp. from Phoenixus AG and others in a reverse merger transaction on May 13, 2021. Phoenixus AG (“PAG”) owns approximately 98.9% stake in Regnum. Upon closing, membership interests in SevenScore will be converted into the right to receive an aggregate of 25.9 million shares of common stock of Regnum. Upon effectiveness of the Merger, (i) each share of Regnum Common Stock issued and outstanding and owned by PAG as of immediately prior thereto shall be cancelled and extinguished without any conversion thereof, and (ii) 22,730,409 shares of Regnum Common Stock will be owned by PAG as a result of conversion of SevenScore membership interests; (ii) 3,147,759 shares of RGMP Common Stock being owned by several other SevenScore members; and (iii) 250,000 shares of Regnum Common Stock being owned by the Regnum shareholders, other than PAG, prior to effectiveness of the Merger. The equity holders, or members, of SevenScore will receive a majority of the shares of common stock of Regnum in the merger. The completion of the Merger is subject to satisfaction to submit a Company Related Action Notification in accordance with Financial Industry Regulatory Authority (FINRA) Rule 6490. The board of directors of Regnum and SevenScore have unanimously approved the transaction. PAG, the majority shareholder of Regnum also approved the transaction. SevenScore Pharmaceuticals, LLC cancelled the acquisition of Regnum Corp. (OTCPK:RGMP) from Phoenixus AG in a reverse merger transaction on September 1, 2021. No fees or penalties were paid in connection with the termination of the agreement.